N@N

Colin Bristow Upgraded (SRPT) to Strong Buy and Increased Target to $158 on, Dec 16th, 2022

Colin Bristow of UBS, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Strong Buy and Increased Target from $100 to $158 on, Dec 16th, 2022.

Colin has made no other calls on SRPT in the last 4 months.

There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $101 on, Thursday, November 3rd, 2022
• Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022

These are the ratings of the 5 analyists that currently disagree with Colin

---

• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $138 on, Tuesday, November 29th, 2022
• Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
• Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
• Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $158 on, Thursday, November 3rd, 2022
• Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022

Contributing Sources

---